Orthofix Medical Inc (NASDAQ: OFIX) reported quarterly results Monday that were broadly in-line with expectations while guiding to higher spending and linear revenue growth.
Investors can look past the guidance and the announcement of CEO Brad Mason's retirement during a turbulent time, but will want more clarity around growth drivers — especially the commercialization of the MC-6 artificial cervical disc, according to BTIG.
BTIG’s Ryan Zimmerman downgrade Orthofix Medical from Buy to Neutral.
Orthofix Medical has indicated modest revenue growth through FY19 and double-digit organic growth in FY20. Uncertainty surrounds how the company will achieve this, Zimmerman said in a Tuesday note.
Although M6-C could result in accelerating growth for the company, the projection of revenue growing by around $48 million in FY20 appears ambitious, the analyst said.
For the company to reach this target, sales of M6-C would need to grow significantly from FY19 levels, along with contributions from the rest of the business, which is currently growing in the low single digits, he said.
Orthofix Medical’s shares could remain rangebound until here is greater clarity around growth drivers, Zimmerman said, adding that shares could “settle several percent lower."
Orthofix Medical shares were down 10.5 percent at $60.60 at the time of publication Tuesday.
The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Latest Ratings for OFIX
|Feb 2019||BTIG Research||Downgrades||Buy||Neutral|
|Jun 2018||Cantor Fitzgerald||Initiates Coverage On||Overweight|
|Jun 2017||BTIG Research||Initiates Coverage On||Buy|
View More Analyst Ratings for OFIX
View the Latest Analyst Ratings
See more from Benzinga
- Oppenheimer Expects 2U To Post Share Gains, Strong Revenue In 2019
- KeyBanc Believes Welbilt 2019 Guidance May Prove Conservative
- After Instructure's Mixed Quarterly Print, Guidance Miss, Oppenheimer Waits For More Clarity
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.